Want to see JP:4519 full AI Analyst Report?

Chugai Pharmaceutical Co (4519) Price & Analysis

4 Followers

4519 Stock Chart & Stats

¥8349.00

-¥136.00(-1.98%)

At close: Jan 08 4:00 PM EST

¥8349.00

-¥136.00(-1.98%)

Day’s Range― - ―

52-Week Range¥5,942.00 - ¥10,700.00

Previous CloseN/A

Volume1.90M

Average Volume (3M)2.77M

Market Cap

¥12.40T

Enterprise Value¥12.03T

Total Cash (Recent Filing)¥850.10B

Total Debt (Recent Filing)¥17.51B

Price to Earnings (P/E)27.4

Beta0.77

Next Earnings

Jul 24, 2026

EPS Estimate

77.88

Next Dividend Ex-DateN/A

Dividend Yield1.17%

Share Statistics

EPS (TTM)274.78

Shares Outstanding1,679,057,600

10 Day Avg. Volume3,088,480

30 Day Avg. Volume2,774,486

Financial Highlights & Ratios

PEG Ratio2.60

Price to Book (P/B)6.70

Price to Sales (P/S)10.78

P/FCF Ratio43.31

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

¥9,722.22

Price Target Upside16.45% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering9

EPS Forecast (FY)309.9

Revenue Forecast (FY)¥1.38T

Bulls Say, Bears Say

Bulls Say

High ProfitabilitySustained, industry-leading margins and ~22% ROE indicate durable pricing power, efficient R&D-to-commercialization, and strong operating leverage. This profitability supports long-term reinvestment in pipeline, stable dividends, and resilience through product cycles without relying on leverage.

Conservative Balance SheetExtremely low leverage and a large equity base provide structural financial flexibility: cushions patent or reimbursement shocks, enables sustained R&D spending or opportunistic bolt-on deals, and reduces refinancing risk across multi-year drug development timelines.

Strategic Roche Partnership & R&D FocusAs part of the Roche group and with close collaboration, Chugai gains scale in global development, shared regulatory expertise, and commercialization reach. This structural alliance de-risks late-stage development and accelerates global market access for its biologics and oncology portfolio.

Bears Say

Uneven Revenue Growth / Product RelianceRevenue has shown volatility, including a notable 2023 contraction and only modest re-acceleration recently. Heavy dependence on a handful of therapeutic franchises and product life-cycle timing means top-line variability can persist, complicating multi-year forecasting and investment pacing.

Variable Cash ConversionTTM operating cash below net income and prior volatility point to working-capital swings and timing effects. This can constrain actual free cash available for buybacks, special investments or higher dividends in some years despite strong accounting earnings, affecting long-term capital allocation predictability.

Balance-sheet Re-mix IndicatorsA recent decline in equity and assets, while leverage remains low, could signal capital returns, restructuring, or asset re-balancing. Over the medium term, such changes deserve monitoring as they may alter surplus capital available for R&D funding or inorganic growth priorities.

Chugai Pharmaceutical Co News

Chugai’s Immunotherapy Combo Trial Reaches Completion: What the Latest Update Means for Investors

Chugai Pharmaceutical Co ($CHGCF) announced an update on their ongoing clinical study. Chugai-linked Cancer Trial Update: What Investors...

13d ago

CHGCF

Chugai Sets Terms for New Trust-Based Stock Compensation Plans

Chugai Pharmaceutical Co ( ($JP:4519) ) has issued an announcement. Chugai Pharmaceutical has approved detailed terms for a...

2M ago

Chugai Results Reflected in Roche’s First-Quarter 2026 Sales Report

Chugai Pharmaceutical Co ( ($JP:4519) ) has shared an update. F. Hoffmann-La Roche, the Swiss healthcare group and...

2M ago

CHGCF Earnings this Week: How Will it Perform?

Chugai Pharmaceutical Co (CHGCF) is scheduled to report 1st quarter earnings on 04/24/2026, before the market opens. Regarding...

2M ago

Chugai Clarifies Strategic Alliance and Governance Structure Under Roche Control

Chugai Pharmaceutical Co ( ($JP:4519) ) has shared an update. Chugai Pharmaceutical has reiterated its position within the...

3M ago

Chugai Weighs Investment Unit Cut to Boost Liquidity and Broaden Investor Base

Chugai Pharmaceutical Co ( ($JP:4519) ) has provided an update. Chugai Pharmaceutical has outlined its stance on reducing...

3M ago

Chugai, Roche Halt Neuromuscular Trials of Emugrobart but Press On in Obesity

Chugai Pharmaceutical Co ( ($JP:4519) ) has shared an announcement. Chugai Pharmaceutical said partner Roche will discontinue development...

3M ago

Chugai and Roche Advance NXT007 Into Phase III, Raising the Stakes in Hemophilia A

Chugai Pharmaceutical Co ($CHGCF) announced an update on their ongoing clinical study. The phase III study “A Multicenter,...

4M ago

CHGCF

Chugai and Roche Advance NXT007 Into Phase III to Challenge Emicizumab in Hemophilia A

Chugai Pharmaceutical Co ($CHGCF) announced an update on their ongoing clinical study. The Phase III study “A Multicenter,...

4M ago

CHGCF

Chugai’s SAIL66 Phase I Completion: What the Latest Trial Update Means for Investors

Chugai Pharmaceutical Co ($CHGCF) announced an update on their ongoing clinical study. The Phase I study titled “A...

4M ago

CHGCF

4519 FAQ

What was Chugai Pharmaceutical Co Ltd’s price range in the past 12 months?

Chugai Pharmaceutical Co Ltd lowest stock price was ¥5942.00 and its highest was ¥10700.00 in the past 12 months.

What is Chugai Pharmaceutical Co Ltd’s market cap?

Chugai Pharmaceutical Co Ltd’s market cap is ¥12.40T.

When is Chugai Pharmaceutical Co Ltd’s upcoming earnings report date?

Chugai Pharmaceutical Co Ltd’s upcoming earnings report date is Jul 24, 2026 which is in 23 days.

How were Chugai Pharmaceutical Co Ltd’s earnings last quarter?

Chugai Pharmaceutical Co Ltd released its earnings results on Apr 24, 2026. The company reported ¥70.13 earnings per share for the quarter, beating the consensus estimate of ¥67.123 by ¥3.007.

Is Chugai Pharmaceutical Co Ltd overvalued?

According to Wall Street analysts Chugai Pharmaceutical Co Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Chugai Pharmaceutical Co Ltd pay dividends?

Chugai Pharmaceutical Co Ltd pays a Notavailable dividend of ¥65 which represents an annual dividend yield of 1.17%. See more information on Chugai Pharmaceutical Co Ltd dividends here

What is Chugai Pharmaceutical Co Ltd’s EPS estimate?

Chugai Pharmaceutical Co Ltd’s EPS estimate is 77.88.

How many shares outstanding does Chugai Pharmaceutical Co Ltd have?

Chugai Pharmaceutical Co Ltd has 1,679,057,600 shares outstanding.

What happened to Chugai Pharmaceutical Co Ltd’s price movement after its last earnings report?

Chugai Pharmaceutical Co Ltd reported an EPS of ¥70.13 in its last earnings report, beating expectations of ¥67.123. Following the earnings report the stock price went down -0.907%.

Which hedge fund is a major shareholder of Chugai Pharmaceutical Co Ltd?

Currently, no hedge funds are holding shares in JP:4519

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Chugai Pharmaceutical Co Ltd

Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.

Chugai Pharmaceutical Co (4519) Earnings & Revenues

Historic Earnings Reports

4519 Company Deck

4519 Earnings Call

Q1 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented a strongly positive financial and operational picture: record FY2025 revenue, operating profit and margin, robust FY2026 guidance, significant clinical and pipeline progress (notably NXT007, giredestrant, Enspryng, orforglipron), and disciplined cost control. Key risks were acknowledged — a serious safety event delaying Elevidys launch, biosimilar and generic pressure on legacy products (Actemra, Avastin), several project discontinuations, and some uncertainty around royalty/milestone timing and cash reduction after special dividends. On balance the call emphasized sustained growth, high profitability and a focused R&D strategy while noting manageable but material risks that warrant monitoring.View all JP:4519 earnings summaries

4519 Stock 12 Month Forecast

Average Price Target

¥9,722.22

▲(16.45% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6348":"¥6,348","13501":"¥13,501","8136.25":"¥8,136.3","9924.5":"¥9,924.5","11712.75":"¥11,712.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":13500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥14K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9722.222222222223,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥10K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥8K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6348,8136.25,9924.5,11712.75,13501],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7595.958,8050.115076923076,8504.272153846154,8958.42923076923,9412.586307692307,9866.743384615384,10320.900461538462,10775.057538461539,11229.214615384615,11683.371692307692,12137.528769230768,12591.685846153847,13045.842923076922,{"y":13500,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7595.958,7759.516786324786,7923.075572649573,8086.634358974359,8250.193145299145,8413.751931623932,8577.310717948718,8740.869504273505,8904.428290598291,9067.987076923077,9231.545863247864,9395.10464957265,9558.663435897437,{"y":9722.222222222223,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7595.958,7627.038153846153,7658.118307692307,7689.198461538461,7720.2786153846155,7751.358769230769,7782.438923076923,7813.519076923077,7844.59923076923,7875.679384615384,7906.759538461538,7937.8396923076925,7968.919846153846,{"y":8000,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7404.331,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7047.375,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7147.676,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6349.162,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6521.524,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6864.301,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7860.496,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8169.818,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8723.854,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10054.932,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8920.097,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8171.8,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7595.958,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >